Telix Pharmaceuticals has announced a $3.3 billion acquisition of Germany’s ITM Isotope Technologies, aimed at creating a leading global nuclear medicine company. Telix will initially pay $1.65 billion for ITM, a firm specializing in cancer diagnostics and treatments, with the potential to increase the total cost to $3.3 billion based on performance milestones, long-term sales targets, and FDA approvals.
Mon, 21 Sep 2026 05:24:00 GMT | AFR